An observational study in Intracerebral Hemorrhage, sponsored by University Hospital, Tours. Recruiting at 3 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-15.
Sponsored by University Hospital, Tours · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Cerebral Hemorrhage with a site in France — 11 open to participants now, 11 under way, 2 of them phase 3. Cerebral Hemorrhage · France.
Among the 24 studies in Cerebral Hemorrhage with a site in France, this one is the 4th largest by planned enrollment of the 11 observational ones that give a count, is the only one that started in 2022, is one of 11 observational ones, reaches primary completion later than 3 of the 10 other live ones, and was the 17th registered.
458 studies on the registry are indexed under Cerebral Hemorrhage; 173 are open to participants now.
Browse Cerebral Hemorrhage studies →11 of the 24 studies in Cerebral Hemorrhage with a site in France are open now. Recruiting first, the newest first:
University Hospital, Tours · Sites in France
Ages 18+
University Hospital, Lille · Sites in France
Ages 18–65 · Healthy volunteers
Centre Hospitalier Universitaire de Nīmes · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
University Hospital, Lille · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 115 Cerebral Hemorrhage studies recruiting now, 61 (53%) set no upper age limit and 9 (8%) stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 1990; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 600 is above the median of 300 across 181 observational studies indexed under Cerebral Hemorrhage.
Median enrollment 300 across the 13 interventional studies, 455 across the 11 observational. Of the 13 that completed or were terminated, 1 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 24 have an industry lead sponsor. The 10 most frequent:
University Hospital, Tours is the lead sponsor of 309 studies on the registry; 81 are open to participants now.
University Hospital, Tours has 2 studies filed under Cerebral Hemorrhage — fewer than ten, so there is no comparison to draw.
2 of the studies in Cerebral Hemorrhage with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06781034Centre Hospitalier Universitaire de NīmesDescriptive Study on MRI Contrast of Acute Cerebral Hemorrhage in Different Microangiopathies | 2026-12 |
| NCT06802588University Hospital, ToursOptimization of the Management of Non-Traumatic Intracerebral Hemorrhage (OPT-ICH) | 2027-05-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 24 studies in Cerebral Hemorrhage with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Intracerebral non-traumatic intraparenchymal hemorrhages (ICH) account for 15 to 20% of strokes. One third of the patients dies within the month following ICH, and survivors often experience residual disability with a high risk of recurrent ICH, other serious vascular events, and neurological complications such as epilepsy and dementia. Encouraging but preliminary data suggest a favorable trend in terms of survival rates in recent years. This is partly due to improved management of patients with ICH, which must be early (the concept of "time is brain") and carried out by expert personnel (medical and paramedical) in specialized units.
The main objectives of the study are:
The project consists of 2 parts:
Each patient will benefit from management according to a protocol which will include:
Adult population with acute ICH
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria :
- Patient who has given their opposition to the collection of their data
mortality and disability
Primary Outcome Measure Title: Modified Rankin Scale (mRS) Scores to Assess Disability and Mortality Description: The study will evaluate functional outcomes, disability, and mortality in patients with non-traumatic intracerebral hemorrhage. Functional outcomes will be measured using the modified Rankin Scale (mRS), which evaluates the degree of disability or dependence in daily activities. The mRS scores range from 0 (no symptoms) to 6 (death). Data will be summarized as the proportion of participants in each mRS category at 6 months and 2 years. Mortality will be assessed as the percentage of participants with an mRS score of 6.
Time frame: 6 months, 2 years
Neuropsychiatric patient profile among the survivors
Cognitive and behavioral outcomes will be measured using a battery of neuropsychiatric tests, including assessments for memory, executive function, attention, and mood disorders (e.g., depression and anxiety). Data will be reported as mean test scores for each domain
Time frame: 6 months, 2 years
Plan to share: No
No publications or documents are linked to this record.
Started May 2022 (actual). Primary completion is estimated for May 2027, 60 months after the start.
Of 88 non-industry observational studies under Cerebral Hemorrhage, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 179. This study's planned 60 months is close to that.
Counting every sponsor, half of 90 studies reached it within 62 months; a quarter within 27 and three quarters within 179.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.